Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Izzy who wrote (3067)	12/2/1997 12:36:00 PM
From: Steve Fancy	of 6136

Well, first word from analysts since earnings...too bad it's a downgrade. RESEARCH ALERT - Agouron (NASDAQ:AGPH) downgraded Reuters, Tuesday, December 02, 1997 at 11:38 NEW YORK, Dec 2 (Reuters) - Bankers Trust Alex.Brown said on Tuesday it cut its rating on shares of Agouron Pharmaceuticals Inc to market perform from a strong buy. -- Analyst not immediately available to comment further. -- Company said on Tuesday it agreed to end its collaboration with F. Hoffmann-La Roche (ZSE:ROCZ.G) in the field of cancer treatment and discontinue further development of its anti-cancer drug AG337, or Thymitag. -- Stock lost 7-1/8 to 32-3/8. Copyright 1997, Reuters News Service

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next